| scholarly article | Q13442814 |
| P50 | author | Yuan-Chi Teng | Q87057418 |
| P2093 | author name string | Ting-Fen Tsai | |
| Cheng-Heng Kao | |||
| Zhao-Qing Shen | |||
| P2860 | cites work | Heterozygous mice for the transforming growth factor-beta type II receptor gene have increased susceptibility to hepatocellular carcinogenesis. | Q43739403 |
| Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus | Q44036705 | ||
| Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus | Q21128797 | ||
| Hallmarks of Cancer: The Next Generation | Q22252312 | ||
| Identification of the gene for a novel liver-related putative tumor suppressor at a high-frequency loss of heterozygosity region of chromosome 8p23 in human hepatocellular carcinoma | Q24290300 | ||
| CIA, a novel estrogen receptor coactivator with a bifunctional nuclear receptor interacting determinant | Q24290613 | ||
| Nucling mediates apoptosis by inhibiting expression of galectin-3 through interference with nuclear factor kappaB signalling | Q24307907 | ||
| Telomerase inhibitor PinX1 provides a link between TRF1 and telomerase to prevent telomere elongation | Q24310189 | ||
| Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor | Q24569647 | ||
| New advances in precision medicine for hepatocellular carcinoma recurrence prediction and treatment | Q87416815 | ||
| Chromosomal instability and cancer: a complex relationship with therapeutic potential | Q24608609 | ||
| Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene | Q24617547 | ||
| Downregulation of miR-122 in the rodent and human hepatocellular carcinomas | Q24631076 | ||
| Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis | Q24632905 | ||
| The interaction of hepatic lipid and glucose metabolism in liver diseases | Q26827770 | ||
| S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility | Q26829356 | ||
| RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis | Q26853207 | ||
| Targeting the ubiquitin pathway for cancer treatment | Q26866185 | ||
| SOCS, inflammation, and cancer | Q26991808 | ||
| Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer | Q26992106 | ||
| Autophagy in malignant transformation and cancer progression | Q27000191 | ||
| Mouse models of hepatitis B virus infection comprising host-virus immunologic interactions | Q27002598 | ||
| Persistent hepatitis B viral replication in a FVB/N mouse model: impact of host and viral factors | Q27302970 | ||
| p53, the cellular gatekeeper for growth and division | Q27860990 | ||
| Nrf1 is critical for redox balance and survival of liver cells during development | Q28179361 | ||
| SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130 | Q28211408 | ||
| Liver-specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasia | Q28237402 | ||
| Clinical significance of increased expression of Nijmegen breakage syndrome gene (NBS1) in human primary liver cancer | Q28265438 | ||
| Genomic instability--an evolving hallmark of cancer | Q28274009 | ||
| Minireview: PRKAR1A: normal and abnormal functions | Q28279040 | ||
| Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma | Q28284012 | ||
| Tumor suppressor and hepatocellular carcinoma | Q28389231 | ||
| Pten is essential for embryonic development and tumour suppression | Q28509238 | ||
| Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems | Q28586004 | ||
| NCOA5 haploinsufficiency results in glucose intolerance and subsequent hepatocellular carcinoma | Q28586911 | ||
| Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver | Q28587974 | ||
| Impairment of starvation-induced and constitutive autophagy in Atg7-deficient mice | Q28588080 | ||
| Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression | Q28591557 | ||
| Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas | Q28592004 | ||
| Absence of the SRC-2 coactivator results in a glycogenopathy resembling Von Gierke's disease | Q28592482 | ||
| Nbn heterozygosity renders mice susceptible to tumor formation and ionizing radiation-induced tumorigenesis | Q28594255 | ||
| Hepatitis B virus nucleocapsid particles do not cross the hepatocyte nuclear membrane in transgenic mice | Q28776764 | ||
| Autophagy regulates lipid metabolism | Q29547421 | ||
| The role of autophagy during the early neonatal starvation period | Q29547489 | ||
| WNT signalling pathways as therapeutic targets in cancer | Q29615666 | ||
| Gp78, an E3 ubiquitin ligase acts as a gatekeeper suppressing nonalcoholic steatohepatitis (NASH) and liver cancer | Q35581153 | ||
| Noncoding RNA as therapeutic targets for hepatocellular carcinoma. | Q35592207 | ||
| Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice | Q35765708 | ||
| NF-κB in the liver--linking injury, fibrosis and hepatocellular carcinoma | Q35808323 | ||
| PTPRO-mediated autophagy prevents hepatosteatosis and tumorigenesis | Q35832384 | ||
| Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis | Q35834086 | ||
| High-level hepatitis B virus replication in transgenic mice | Q35847850 | ||
| Interleukin-12 inhibits hepatitis B virus replication in transgenic mice | Q35881471 | ||
| Targeting the interleukin-6/Jak/stat pathway in human malignancies | Q35925127 | ||
| Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma | Q35945177 | ||
| Hepatocarcinogenesis in FXR-/- mice mimics human HCC progression that operates through HNF1α regulation of FXR expression | Q35970148 | ||
| A Sleeping Beauty mutagenesis screen reveals a tumor suppressor role for Ncoa2/Src-2 in liver cancer. | Q35991536 | ||
| Sak/Plk4 and mitotic fidelity | Q36004665 | ||
| MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis | Q36129123 | ||
| Enhanced hepatocarcinogenesis in mouse models and human hepatocellular carcinoma by coordinate KLF6 depletion and increased messenger RNA splicing | Q36141301 | ||
| Tumor suppressor genetics | Q36252762 | ||
| Tumor development: haploinsufficiency and local network assembly | Q36285535 | ||
| HBV induced carcinogenesis | Q36388400 | ||
| Hepatitis B virus X protein targets Bcl-2 proteins to increase intracellular calcium, required for virus replication and cell death induction | Q36389447 | ||
| Hepatitis B virus X protein targets the Bcl-2 protein CED-9 to induce intracellular Ca2+ increase and cell death in Caenorhabditis elegans | Q36389497 | ||
| Immune pathogenesis of hepatocellular carcinoma. | Q36401448 | ||
| SOCS1 is a suppressor of liver fibrosis and hepatitis-induced carcinogenesis | Q36402678 | ||
| Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. | Q36497062 | ||
| Hepatitis B virus-related hepatocellular carcinoma: paradigms for viral-related human carcinogenesis | Q36519025 | ||
| Hepatitis B virus pre-S mutants, endoplasmic reticulum stress and hepatocarcinogenesis | Q36545096 | ||
| TRIM24 suppresses development of spontaneous hepatic lipid accumulation and hepatocellular carcinoma in mice | Q36633583 | ||
| Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice | Q36688699 | ||
| Defects in inositol 1,4,5-trisphosphate receptor expression, Ca(2+) signaling, and insulin secretion in the anx7(+/-) knockout mouse | Q36701660 | ||
| Hepatitis B virus transactivator X protein is not tumorigenic in transgenic mice | Q36796019 | ||
| Tissue preferential expression of the hepatitis B virus (HBV) surface antigen gene in two lines of HBV transgenic mice | Q36827049 | ||
| Developmental regulation of hepatitis B surface antigen expression in two lines of hepatitis B virus transgenic mice | Q36830784 | ||
| Expression of hepatitis B virus large envelope polypeptide inhibits hepatitis B surface antigen secretion in transgenic mice | Q36869563 | ||
| Hepatic stem cells and transforming growth factor β in hepatocellular carcinoma | Q37099380 | ||
| Viral hepatocarcinogenesis: from infection to cancer | Q34587991 | ||
| Hepatitis B surface antigen gene expression is regulated by sex steroids and glucocorticoids in transgenic mice | Q34599361 | ||
| Genetic mechanisms of hepatocarcinogenesis | Q34611410 | ||
| Hepatocellular carcinoma: insight from animal models | Q34633249 | ||
| MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches. | Q34675280 | ||
| Tumor suppressor gene-based nanotherapy: from test tube to the clinic | Q34730883 | ||
| Targeting Hepatitis B Virus With CRISPR/Cas9. | Q34745348 | ||
| Regulatory elements of hepatitis B virus transcription | Q34842064 | ||
| Autophagy suppresses tumorigenesis of hepatitis B virus-associated hepatocellular carcinoma through degradation of microRNA-224. | Q34984034 | ||
| The regulation of inflammation by galectin-3. | Q34991925 | ||
| Pre-S2 deletion mutants of hepatitis B virus could have an important role in hepatocarcinogenesis in Asian children. | Q35000423 | ||
| Nijmegen breakage syndrome gene, NBS1, and molecular links to factors for genome stability | Q35026390 | ||
| Overexpression of TRIM24 is associated with the onset and progress of human hepatocellular carcinoma | Q35084843 | ||
| NF-κB addiction and its role in cancer: 'one size does not fit all'. | Q35120893 | ||
| Carcinogen-induced hepatic tumors in KLF6+/- mice recapitulate aggressive human hepatocellular carcinoma associated with p53 pathway deregulation. | Q35131908 | ||
| Parkin is a lipid-responsive regulator of fat uptake in mice and mutant human cells | Q35208410 | ||
| Sgo1 is a potential therapeutic target for hepatocellular carcinoma | Q35273343 | ||
| NF-κB and STAT3 - key players in liver inflammation and cancer | Q35347976 | ||
| Tumor-promoting/progressing role of additional chromosome instability in hepatic carcinogenesis in Sgo1 (Shugoshin 1) haploinsufficient mice | Q35356022 | ||
| Deletion of betaine-homocysteine S-methyltransferase in mice perturbs choline and 1-carbon metabolism, resulting in fatty liver and hepatocellular carcinomas | Q35379075 | ||
| Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma | Q37138658 | ||
| Tenets of PTEN tumor suppression | Q37154214 | ||
| Pivotal role of mTOR signaling in hepatocellular carcinoma | Q37183244 | ||
| Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma | Q37284612 | ||
| LKB1; linking cell structure and tumor suppression | Q37333592 | ||
| Role of bile acids and bile acid receptors in metabolic regulation | Q37363616 | ||
| APC promoter methylation and protein expression in hepatocellular carcinoma | Q37376713 | ||
| CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes | Q37448141 | ||
| Comparative PRKAR1A genotype-phenotype analyses in humans with Carney complex and prkar1a haploinsufficient mice | Q37557334 | ||
| Then and now: the progress in hepatitis B treatment over the past 20 years | Q37581346 | ||
| TGF-β: duality of function between tumor prevention and carcinogenesis. | Q37634488 | ||
| Identification of novel oncogenes and tumor suppressors in hepatocellular carcinoma | Q37696402 | ||
| The role of signaling pathways in the development and treatment of hepatocellular carcinoma | Q37773788 | ||
| Autophagy in liver diseases. | Q37784560 | ||
| Haplo-insufficiency: a driving force in cancer | Q37815124 | ||
| Biology of Krüppel-like factor 6 transcriptional regulator in cell life and death | Q37820607 | ||
| Switching TGFβ from a tumor suppressor to a tumor promoter. | Q37830876 | ||
| Hepatitis B therapy | Q37855531 | ||
| Genetics of hepatobiliary carcinogenesis | Q37871482 | ||
| Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): an emerging field for advanced technologies. | Q37904165 | ||
| Bile acids: from digestion to cancers | Q38024178 | ||
| gp78: a multifaceted ubiquitin ligase that integrates a unique protein degradation pathway from the endoplasmic reticulum | Q38027564 | ||
| Bile acid transporters and regulatory nuclear receptors in the liver and beyond | Q38033967 | ||
| p21WAF1 and tumourigenesis: 20 years after | Q38060451 | ||
| S-adenosylmethionine metabolism and liver disease. | Q38080431 | ||
| Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistance | Q38081267 | ||
| The mTOR pathway in hepatic malignancies | Q38081396 | ||
| The role of autophagy in liver cancer: molecular mechanisms and potential therapeutic targets | Q38083383 | ||
| Mouse models for liver cancer. | Q38083387 | ||
| Potential role of annexin A7 in cancers | Q38103681 | ||
| An Overview of Hepatitis B Virus Surface Antigen Mutant in the Asia Pacific | Q38135400 | ||
| Mice with human livers | Q38138332 | ||
| Krüppel-like factors in cancer | Q38141516 | ||
| An emerging role of PARK2 in cancer | Q38168127 | ||
| Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway | Q38170894 | ||
| The role and therapeutic implications of RING-finger E3 ubiquitin ligases in hepatocellular carcinoma | Q38178169 | ||
| Molecular insights into NF2/Merlin tumor suppressor function | Q38204110 | ||
| Caught up in a Wnt storm: Wnt signaling in cancer | Q29617494 | ||
| Epidemiology of viral hepatitis and hepatocellular carcinoma | Q29617918 | ||
| Immunology of hepatitis B virus and hepatitis C virus infection | Q29618957 | ||
| The Hippo signaling pathway in stem cell biology and cancer | Q30410176 | ||
| Characterization of glycine-N-methyltransferase-gene expression in human hepatocellular carcinoma | Q32100816 | ||
| Haploinsufficiency of Anx7 tumor suppressor gene and consequent genomic instability promotes tumorigenesis in the Anx7(+/-) mouse | Q33194830 | ||
| Correlation between expression of p53, p21/WAF1, and MDM2 proteins and their prognostic significance in primary hepatocellular carcinoma | Q33601430 | ||
| Type beta transforming growth factor reversibly inhibits the early proliferative response to partial hepatectomy in the rat. | Q33632161 | ||
| Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? | Q33762446 | ||
| In vivo regulation of hepatitis B virus replication by peroxisome proliferators | Q33825523 | ||
| Expression and replication of hepatitis B virus genome in transgenic mice | Q33828858 | ||
| Nuclear covalently closed circular viral genomic DNA in the liver of hepatocyte nuclear factor 1 alpha-null hepatitis B virus transgenic mice | Q33865967 | ||
| Role of Wnt/β-catenin signaling in liver metabolism and cancer | Q33940403 | ||
| Late mitotic failure in mice lacking Sak, a polo-like kinase. | Q33942360 | ||
| Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver | Q34069370 | ||
| The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals | Q34077795 | ||
| Nrf2 promotes the development of fibrosis and tumorigenesis in mice with defective hepatic autophagy | Q34086698 | ||
| The telomerase inhibitor PinX1 is a major haploinsufficient tumor suppressor essential for chromosome stability in mice | Q34173242 | ||
| The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors | Q34218976 | ||
| NF-E2-related factor 1 (Nrf1) serves as a novel regulator of hepatic lipid metabolism through regulation of the Lipin1 and PGC-1β genes | Q34274999 | ||
| MicroRNA-140 acts as a liver tumor suppressor by controlling NF-κB activity by directly targeting DNA methyltransferase 1 (Dnmt1) expression. | Q34294469 | ||
| Complex interactions between microRNAs and hepatitis B/C viruses | Q34302987 | ||
| S-adenosylmethionine in liver health, injury, and cancer | Q34306534 | ||
| Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice. | Q34350113 | ||
| Structural and pathological effects of synthesis of hepatitis B virus large envelope polypeptide in transgenic mice | Q34350664 | ||
| The emerging role of hepatitis B virus pre-S2 deletion mutant proteins in HBV tumorigenesis. | Q34354947 | ||
| Hepatitis B virus X protein upregulates mTOR signaling through IKKβ to increase cell proliferation and VEGF production in hepatocellular carcinoma | Q34359262 | ||
| NAFLD, NASH and liver cancer | Q34374372 | ||
| Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas | Q34380511 | ||
| Autophagy-preferential degradation of MIR224 participates in hepatocellular carcinoma tumorigenesis | Q34388829 | ||
| Autophagy and apoptosis-related genes in chronic liver disease and hepatocellular carcinoma. | Q34396410 | ||
| The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo | Q34459390 | ||
| Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level | Q34481474 | ||
| Hepatocellular carcinoma caused by loss of heterozygosity in Lkb1 gene knockout mice | Q34526330 | ||
| Hippo-YAP signaling pathway: A new paradigm for cancer therapy | Q38231786 | ||
| Hepatocellular carcinoma epidemiology | Q38254688 | ||
| Hippo pathway regulation of gastrointestinal tissues | Q38257899 | ||
| Hepatocellular carcinoma and microRNA: new perspectives on therapeutics and diagnostics | Q38275679 | ||
| Shugoshins: tension-sensitive pericentromeric adaptors safeguarding chromosome segregation | Q38276217 | ||
| Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. | Q38310253 | ||
| The JAK-STAT pathway: impact on human disease and therapeutic intervention | Q38317993 | ||
| Identification of the common regulators for hepatocellular carcinoma induced by hepatitis B virus X antigen in a mouse model. | Q38330894 | ||
| Hitting cancers' weak spots: vulnerabilities imposed by p53 mutation | Q38470609 | ||
| Incidence of hepatocellular carcinoma in transgenic mice expressing the hepatitis B virus X-protein | Q38527672 | ||
| miR-375 inhibits autophagy and reduces viability of hepatocellular carcinoma cells under hypoxic conditions | Q39364639 | ||
| The molecular biology of the hepatitis B viruses | Q39511089 | ||
| Association of autophagy defect with a malignant phenotype and poor prognosis of hepatocellular carcinoma | Q39916459 | ||
| Disruption of transforming growth factor-beta signaling through beta-spectrin ELF leads to hepatocellular cancer through cyclin D1 activation | Q40124427 | ||
| Replication and gene expression of hepatitis B virus in a transgenic mouse that contains the complete viral genome | Q40130886 | ||
| Reduced expression of CYLD in human colon and hepatocellular carcinomas | Q40267883 | ||
| Hepatitis B virus pre-S2 mutant upregulates cyclin A expression and induces nodular proliferation of hepatocytes. | Q40455477 | ||
| Parkin gene alterations in hepatocellular carcinoma | Q40564245 | ||
| A transgenic mouse model of the chronic hepatitis B surface antigen carrier state | Q41483768 | ||
| A biphasic response pattern of lipid metabolomics in the stage progression of hepatitis B virus X tumorigenesis | Q41540811 | ||
| Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease | Q41566723 | ||
| Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice | Q41736950 | ||
| Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice | Q41757834 | ||
| Autophagy-deficient mice develop multiple liver tumors | Q42099409 | ||
| A quantitative proteomic approach for identification of potential biomarkers in hepatocellular carcinoma | Q42594913 | ||
| Resveratrol helps recovery from fatty liver and protects against hepatocellular carcinoma induced by hepatitis B virus X protein in a mouse model | Q42717718 | ||
| Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition | Q42718504 | ||
| Parkin as a tumor suppressor gene for hepatocellular carcinoma | Q42811415 | ||
| Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma | Q43049041 | ||
| Hepatitis B injury, male gender, aflatoxin, and p53 expression each contribute to hepatocarcinogenesis in transgenic mice | Q43601327 | ||
| Hepatocarcinogenesis due to chronic liver cell injury in hepatitis B virus transgenic mice | Q44184480 | ||
| Thirty-year outcomes of the national hepatitis B immunization program in Taiwan | Q44712948 | ||
| Production and effect of infectious Dane particles in transgenic mice | Q44984147 | ||
| Blocking of G1/S transition and cell death in the regenerating liver of Hepatitis B virus X protein transgenic mice | Q45420975 | ||
| The hepatitis B virus-trimera mouse: a model for human HBV infection and evaluation of anti-HBV therapeutic agents. | Q45751631 | ||
| High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice | Q45779177 | ||
| Hepatic preneoplasia in hepatitis B virus transgenic mice | Q45782995 | ||
| HBx gene of hepatitis B virus induces liver cancer in transgenic mice | Q45852802 | ||
| Characterization of T-cell tolerance to hepatitis B virus (HBV) antigen in transgenic mice | Q45868334 | ||
| IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages | Q46376203 | ||
| Expression of galectin-3 involved in prognosis of patients with hepatocellular carcinoma | Q46442908 | ||
| Metabolic factors and risk of hepatocellular carcinoma by chronic hepatitis B/C infection: a follow-up study in Taiwan. | Q46573520 | ||
| Chemopreventive effect of silymarin on liver pathology in HBV X protein transgenic mice | Q46702642 | ||
| Transforming growth factor-beta1 is a new form of tumor suppressor with true haploid insufficiency. | Q47852627 | ||
| Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism | Q47982118 | ||
| Estrogen-sensitive PTPRO expression represses hepatocellular carcinoma progression by control of STAT3. | Q51323736 | ||
| Disrupted galectin-3 causes non-alcoholic fatty liver disease in male mice. | Q52574179 | ||
| Disruption of Trp53 in livers of mice induces formation of carcinomas with bilineal differentiation. | Q52621794 | ||
| p21 ablation in liver enhances DNA damage, cholestasis, and carcinogenesis. | Q53224670 | ||
| TRIM proteins and cancer. | Q53280723 | ||
| TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer. | Q53299056 | ||
| Nonalcoholic steatohepatitis and hepatocellular carcinoma in galectin-3 knockout mice. | Q53319230 | ||
| Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. | Q53344106 | ||
| Plk4 haploinsufficiency causes mitotic infidelity and carcinogenesis. | Q53356205 | ||
| HBsAg and HBx knocked into the p21 locus causes hepatocellular carcinoma in mice. | Q53370903 | ||
| p21Cip1 nullizygosity increases tumor metastasis in irradiated mice. | Q53378608 | ||
| Constitutive activation of NF-kappaB in human hepatocellular carcinoma: evidence of a cytoprotective role. | Q53631902 | ||
| Inactivation of the deubiquitinase CYLD in hepatocytes causes apoptosis, inflammation, fibrosis, and cancer. | Q54305213 | ||
| Hepatobiliary transporter expression in human hepatocellular carcinoma. | Q54674953 | ||
| Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma. | Q54695730 | ||
| Hepatocellular carcinoma development induced by conditional beta-catenin activation in Lkb1+/- mice. | Q54727263 | ||
| Mutational and expressional analyses of ATG5, an autophagy-related gene, in gastrointestinal cancers. | Q55054516 | ||
| High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice | Q58378937 | ||
| Deletion of NEMO/IKKγ in Liver Parenchymal Cells Causes Steatohepatitis and Hepatocellular Carcinoma | Q58619568 | ||
| Sh(i)pping signals protect against Stat3-driven liver cancer | Q59198940 | ||
| Specific expression of hepatitis B surface antigen (HBsAg) in transgenic mice | Q59890897 | ||
| Sh(i)pping signals protect against Stat3-driven liver cancer | Q62176883 | ||
| Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma | Q62727088 | ||
| HBV production in transgenic mice | Q68582773 | ||
| Extrathymic expression of the intracellular hepatitis B core antigen results in T cell tolerance in transgenic mice | Q72712084 | ||
| Expression of p27(KIP1) and p21(WAF1/CIP1) in primary hepatocellular carcinoma: clinicopathologic correlation and survival analysis | Q74421318 | ||
| Molecular pathogenesis of human hepatocellular carcinoma | Q74543031 | ||
| Transforming growth factor betas and their signaling receptors in human hepatocellular carcinoma | Q77373481 | ||
| Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas | Q77554578 | ||
| ANXA7 expression represents hormone-relevant tumor suppression in different cancers | Q80817271 | ||
| NEMO expression in human hepatocellular carcinoma and its association with clinical outcome | Q82999544 | ||
| Genomic instability and cancer: an introduction | Q83325039 | ||
| The cell cycle and cancer | Q85077091 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | haploinsufficiency | Q852654 |
| hepatocellular carcinoma | Q1148337 | ||
| Hepatitis B virus | Q6844 | ||
| virology | Q7215 | ||
| P304 | page(s) | 300-325 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Hepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genes | |
| P478 | volume | 22 |
| Q64111560 | Anemoside B4 exerts anti-cancer effect by inducing apoptosis and autophagy through inhibiton of PI3K/Akt/mTOR pathway in hepatocellular carcinoma |
| Q90462059 | Animal Models of Hepatocellular Carcinoma: The Role of Immune System and Tumor Microenvironment |
| Q54252192 | Characterizing the Role of Monocytes in T Cell Cancer Immunotherapy Using a 3D Microfluidic Model. |
| Q37317562 | Dual oncogenic and tumor suppressor roles of the promyelocytic leukemia gene in hepatocarcinogenesis associated with hepatitis B virus surface antigen |
| Q47129380 | Gene expression, regulation of DEN and HBx induced HCC mice models and comparisons of tumor, para-tumor and normal tissues |
| Q37481056 | Positive association between serum apolipoprotein M levels and hepatitis B virus DNA load in HBeAg-negative chronic hepatitis B. |
| Q33590673 | Significant symptoms alleviation and tumor volume reduction after combined simultaneously integrated inner-escalated boost and volumetric-modulated arc radiotherapy in a patient with unresectable bulky hepatocellular carcinoma: A care-compliant [...] |
| Q39493086 | The mechanism of apoliprotein A1 down-regulated by Hepatitis B virus |
Search more.